全球抗体类药物市场前景总结与预测.pptVIP

* Soliris No information of this CA patent * 22-Perjeta Pertuzumab a recombinant humanized monoclonal antibody target the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) FDA approval--June 8, 2012 HER2-positive metastatic breast cancer * Perjeta * 24-Botox OnabotulinumtoxinA FDA approval December 9, 1991 * Potentials Avastin Rituxan or Gazyvaro GLP-1 Anti-TNFa MAb (Humira, Enbrel) ? Soliris * Next Phase III or filed projects PD-1 PCSK9 VEGF2 … * * 在口服糖负荷后所引起的胰岛素反应要强于相似血糖谱时静脉糖负荷所引起的胰岛素反应。这个现象被称作“肠促胰岛激素效应”，因为它是由于口服葡萄糖而非静脉注射葡萄糖后所导致的肠促胰岛素激素的分泌所引起. 在人类和动物模型的研究中显示肠促胰岛素激素GLP-1和GIP几乎能够起到所有肠促胰岛素对摄入的营养的处置的效应. 一项临床研究显示，与代谢正常的健康对照(n=8)相比，2型糖尿病患者(n=14)肠促胰岛素效应减弱. 如图所示，口服糖负荷组和静脉给予糖负荷组所产生的血糖谱基本相似.在对照组中和2型糖尿病组中均做了这种匹配的口服和静脉糖负荷. 幻灯底部的图片通过血浆免疫反应胰岛素水平的增加反映了Beta细胞的分泌反应. 这些图片显示在2型糖尿病患者中血浆IR胰岛素峰值延迟并降低。尽管两组口服糖负荷后的胰岛素水平均高于静脉糖负荷，但糖尿病患者的肠促胰岛素效应仍明显减弱。. References: 1. Vilsb?ll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004;47:357–366. 2. Nauck M, St?ckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46–52. * Victoza liraglutide once-daily Approved by FDA on January 25, 2010 Phase I trials of an oral variant of Victoza (NN9924) started in 2010 进入中国市场 (利拉鲁肽 ) * GLP-1: Glucagon-like peptide-1 胰高血糖素样肽 Inducing glucose-dependent stimulation of insulin secretion -- low risk of hypoglycemia Suppressing glucagon secretion Restore the glucose sensitivity of pancreatic β-cells Inhibit pancreatic β-cell apoptosis weight loss …… * Time, min IR Insulin, mU/L 80 60 40 20 0 180 60 120 0 健康对照 (n=8) 2型糖尿病患者 (n=14) Time, min IR Insulin, mU/L 80 60 40 20 0 180 60 120 0 口服糖负荷 静脉葡萄糖输注 正常的肠促胰岛激素效应 减弱的肠促胰岛激素效应 IR = immunoreactive Adapted with permission from Nauck M et al. Diabetologia 1986;29:46–52. Copyright ? 1986 Springer-Verlag. Vilsb?ll T, Holst JJ. Diabetologia 2004;47:357–366. Type 2 diabetes—weaked inc